Innoviva, Inc.: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 9, 2023 and accepted by EDGAR at May 9, 2023, 17:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $76.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2023-01-01 to 2023-03-31 | $12.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-01-01 to 2023-03-31 | $19.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months2023-01-01 to 2023-03-31 | $4.4m | us-gaap:InterestExpense |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $6.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | $34.9m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | $0.42 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | $0.51 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 89,788,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | $25.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-01-01 to 2023-03-31 | $33.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months2023-01-01 to 2023-03-31 | $40.7m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-03-31 | $144.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $296.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $1.13bn | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $38.1m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2023-03-31 | $444.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-03-31 | $0 | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2023-03-31 | $561.5m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0000950170-23-019835. Last ingested by Listed: Oct 27, 2026, 17:26 ET. Listed shows no prices and gives no investment advice.